Moleculin Biotech, Inc.
For the period ended Aug 14, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Aug 14, 2026 · Filed Aug 14, 2026
Use the contents to explore the available documents and sections.
MBRX$8.70-0.3%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Additional Pipeline Programs
Additional Pipeline Programs
Moleculin continues to support development activities for WP1066 through investigator-sponsored and externally funded studies, while maintaining its focus on advancing Annamycin as the Company's lead clinical program.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.